Skip to content

The study aims to quantify cancer causing chemicals in different brands of smokeless tobacco (SLT) products . In addition, levels of these cancer causing chemicals will be estimated in urine samples to study the relationship between tobacco exposure and cancer causation.

Analytical capacity building for the study of tobacco carcinogen exposures in India - Tobacco Carcinogen Exposure Study (T-CARES Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/10/010220
Enrollment
450
Registered
2017-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Oral Head and Neck Cancers

Interventions

None listed

Sponsors

Dr Samir Khariwala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Male of female adult SLT users b. Used the same product variety for more than 80% of their smokeless tobacco over the course of at least 1 year, and used this variety at least 2 weeks prior to the eligibility screening c. Not smoking or using any other nicotine or tobacco product. d. subjects in stable and good mental health (i.e. capable to understand the study, consent and complete study procedures) e.Subjects who have provided written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: a. Regular smoking or tobacco use (e.g. greater than weekly) other than usual SLT products. b. Currently using nicotine replacement or other tobacco cessation products ( to minimize confounding effects of another product) c. Pregnant women d. Prisoners

Design outcomes

Primary

MeasureTime frame
1. To measure the variation in NNN and NNK levels across tobacco products. 2. To prove that after adjustment for duration and intensity of product use, higher carcinogen levels in SLT products will lead to higher biomarker levels in users. 3. To prove that OHNC patients will have higher levels of biomarkers than SLT users without cancer. Timepoint: Spot sampling (once only)

Secondary

MeasureTime frame
Capacity building and sustained collaboration 1. National tobacco product repository at Healis-Sekhsaria Institute for Public Health in Mumbai 2. Biospecimen repository: Samples collected from SLT users will be part of the biospecimen repository which will be hosted by the Tata Memorial Hospital 3.Strengthening laboratory capacity at ACTREC will serve not only to complete the proposed studies, but also as a critical long-term resource for other tobacco exposure studies in India.Timepoint: Not applcable

Countries

India

Contacts

Public ContactDr Pankaj Chaturvedi

Advanced Centre for Treatment, Research and Education in Cancer

vikramgota@gmail.com02227405000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026